ResMed shares are up 42% in a year. This shows why they could still be great value

The investing pros at Firetrail forecast another strong year for ResMed shares in 2025.

| More on:
A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One year ago, on 15 January 2024, you could have bought ResMed Inc (ASX: RMD) shares for $26.00 apiece.

In intraday trade today, shares in the S&P/ASX 200 Index (ASX: XJO) sleep disorder treatment company are changing hands $36.92 each. That sees the ASX 200 healthcare stock up 42% over 12 months. Or almost four times the 10.1% gains posted by the ASX 200 over this same period.

And that's not even including the 21.4 cents a share in unfranked dividends ResMed paid out over the year.

But with those outsized gains already come and gone, can the healthcare company keep on delivering in 2025?

According to the investing pros at Firetrail, that's very possible.

Why ResMed shares can keep charging ahead in 2025

In Firetrail's December High Conviction Fund update, the investment manager reported it had an overweight holding of ResMed shares, with the ASX 200 healthcare stock counting among the top contributors to its returns.

Firetrail noted that 2024 saw a marked turnaround for ResMed after the stock came under selling pressure in 2023 amid investor jitters over the fast rise of GLP1 drugs, which are used to help manage diabetes and obesity.

"It was back in August 2023 that concerns around the impact of GLP1 drugs drove a swift and aggressive selloff in ResMed shares," Firetrail said.

The fund manager continued:

Indeed, ResMed was among the largest detractors for the High Conviction Fund in 2023. However, throughout 2024 our bottom-up conviction and patience were rewarded as ResMed shares outperformed the ASX 200 by 35%.

In their bullish assessment for the outlook of ResMed stock in 2025, Firetrail's analysts pointed to a divergence in the company's price to earnings (P/E) ratio.

"Despite a more balanced emerging view on the impacts of GLP1s, ResMed's relative PE multiple has not recovered since the initial August 2023 selloff," Firetrail said.

Firetrail added:

ResMed's share price rise in 2024 has been entirely driven by earnings revisions. Consensus FY 2025 earnings per share (EPS) in Aussie dollars is now 26% higher than it was at the start of the year, driven by strong continued revenue growth and a recovery of gross margins.

The fund manager included the below graph to illustrate the divergence.

Summing up their optimistic outlook for ResMed shares in 2025, Firetrail said:

While the debate over the ultimate impact of GLP1s remains dynamic, we continue to see earnings upside for ResMed supported by a dominant market position and increased awareness of sleep apnoea.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »